Kymera Therapeutics (KYMR) Net Cash Flow (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Net Cash Flow data on file, last reported at -$212.9 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 603.21% year-over-year to -$212.9 million in Q1 2026; TTM through Mar 2026 was $54.1 million, a 1619.57% increase from a year earlier, with the FY2025 full-year figure at $236.8 million, up 2204.69% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$212.9 million, down from $244.1 million in the prior quarter.
• Over the last five years, Net Cash Flow for KYMR reached as high as $245.9 million in Q2 2025 and fell as low as -$222.9 million in Q3 2025.
• Historically, Net Cash Flow has averaged $5.6 million across 5 years, with a median of $1.9 million in 2023.
• Across the five-year window, Net Cash Flow plunged 1470.87% in 2024 and surged 2456.02% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$87.2 million in 2022, then soared by 133.16% to $28.9 million in 2023, then slumped by 66.99% to $9.5 million in 2024, then jumped by 2456.02% to $244.1 million in 2025, then sank by 187.23% to -$212.9 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$212.9 million in Q1 2026, $244.1 million in Q4 2025, and -$222.9 million in Q3 2025.